

# Zydus' Non-Steroidal Painkiller Receives FDA Final Nod

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in conditions such as arthritis, ankylosing spondylitis, and menstrual pain.



Ahmedabad: Zydus Lifesciences announced that its nonsteroidal anti-inflammatory drug (NSAID), Celecoxib, has received final approval from the U.S. Food and Drug Administration (FDA).

Celecoxib is used to manage pain and inflammation associated with conditions like arthritis, ankylosing spondylitis, and menstrual pain.

The approved drug is the generic version of Celebrex, originally marketed by Pfizer.

Citing IQVIA estimates, Zydus stated that, as of May 2025, the drug has a Moving Annual Turnover (MAT) of \$122.6 million (approximately ₹1,000 crore) in the U.S. market.

With this approval, the group now has 428 drug approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since the initiation of its filing process in FY 2003–04.

## **News Source:**

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/zydus-receives-fda-approval-for-celecoxib-a-non-steroidal-painkiller/122511298>